Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT05903027Recruiting

Gepant treAtments: EffectIveNess and tolERability (GAINER)

Role: collaborator

NCT06414044Active Not Recruiting

Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients

Role: collaborator

NCT06409832Recruiting

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Role: collaborator

NCT05903040Completed

Ditan Acute tReatments: Effectiveness and Tolerability (DART)

Role: collaborator

NCT07126353Not Yet Recruiting

Metabolic Risk Assessment in Prepubertal Children With Congenital Hypothyroidism

Role: collaborator

NCT06773260Enrolling By Invitation

Liver and Spleen Stiffness to Predict the Presence of Esaphageal Varices in Cirrhotic With Advanced HCC

Role: lead

NCT06472063Recruiting

Upfront Surgery Versus NeoAdjuvant Chemotherapy Followed by Surgery for Resectable Advanced Gastric Cancer: SNAC Study

Role: collaborator

NCT06455956Recruiting

Use of miRNAs in Growth Hormone Deficiency (GHD)

Role: collaborator

NCT06409845Recruiting

Effectiveness and Tolerability of Eptinezumab

Role: collaborator

NCT06204523Unknown

Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer

Role: collaborator

NCT04832555Not ApplicableRecruiting

Non Elective Vulnerable Elderly Radiotherapy

Role: lead

All 11 trials loaded